<DOC>
	<DOCNO>NCT01842256</DOCNO>
	<brief_summary>The purpose study investigate effect telmisartan/s-amlodipine pharmacokinetic property atorvastatin .</brief_summary>
	<brief_title>Study Investigate Effect Telmisartan/S-amlodipine Pharmacokinetic Properties Atorvastatin .</brief_title>
	<detailed_description>healthy subject administrate single-dose period Ⅰand Ⅱ ( Crossover ) telmisartan/s-amlodipine , atorvastatin atorvastatin .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Between 20 age 45 age healthy male female 2 . Body weight 55kg male , 50kg female 3 . Body Mass Index 18.5 25 ( Body Mass Index ( kg/m2 ) = kg/ ( ) 2 ) 4 . If female , must include one among item 1 . The menopause ( natural menses least 2 year ) 2 . Surgical Infertility ( hysterectomy bilateral oophorectomy , tubal ligation method infertility condition ) 3 . The male partner infertility screening ( Demonstrated azoospermia vasectomy ) man partner female subject . 4. use one follow contraceptive measure 3 month screen , Necessarily agree use continuously contraceptive measure clinical trial 1 month final dosing investigational product . ( But , use device contraception oral contraceptive drug contain hormonal caused telmisartan , samlodipine , atorvastatin calcium drug interaction clinical trial ) Abstinence . Physical interrupt method ( condom , contraceptive diaphoretic cervical cap ) 5 . In case woman childbearing age , serum βhCG pregnancy test negative , urine βhCG test negative take investigational product . 5 . If men sexual life woman childbearing age , Necessarily agree use condom clinical trial sperm donation clinical trial one month final dosage investigational product 6 . Those fully understand clinical trial enough hearing , decide join clinical trial comply precaution write consent . 1 . Have clinically significant disease hepatobiliary system ( severe hepatic impairment , etc ) , kidney ( severe renal impairment , etc . ) , nervous system , immune system , respiratory system , endocrine system , hematooncology disease , cardiovascular system ( heart failure , etc . ) .or mental illness , history mental disease . 2 . Have gastrointestinal disease history affect drug absorption ( Crohn , ulcer , etc . ) surgery ( except simple appendectomy hernia surgery ) 3 . Hypersensitivity reaction drug clinically significant hypersensitivity reaction history Investigational drug ( telmisartan , samlodipine atorvastatin calcium ) additives 4 . An impossible one participate clinical trial include screen test ( medical history taking , BP , physical examination , 12lead ECG , blood &amp; urine laboratory test result ) within 28 day begin study treatment . 5 . Defined follow laboratory parameter : AST , ALT &gt; 1.25*upper limit normal range Total bilirubin &gt; 1.5* upper limit normal range CPK &gt; 1.5* upper limit normal range eGFR ( use MDRD method ) &lt; 60 mL/min/1.73m2 6 . Sitting SBP &gt; 150 mmHg &lt; 90 mmHg , Sitting DBP &gt; 100 mmHg &lt; 50 mmHg , 5minuts break . 7 . Drug abuse history drug abuse show positive Triage TOX drug urine . 8 . Pregnant lactating woman . 9 . A heavy caffeine consumer ( caffeine &gt; 5cups/day ) , alcohol consumer ( alcohol &gt; 210g/week ) , smoker ( cigarette &gt; 10cigarettes /day ) 10 . Subject take ethical drug herbal medicine within 14days , OTC within 7days begin study treatment investigator determine take drug affect study could affect safety subject . 11 . Subject take inhibitor inducer drug metabolize enzyme ( Barbiturates etc . ) within 30 day . 12 . Taking food contain grapefruit within 7 day begin study treatment ( ex . Drinking contain grapefruit 1L per day within 7 day begin study treatment ) 13 . Subject treat investigational drug within 60days begin study treatment ( However , biologicals applies 90 day , base extended period time consider halflife . 14 . Previously donate whole blood within 60 day component blood within 30days . 15 . An impossible one participant clinical trial investigator 's decision include laboratory test result another reason . 16 . Positive Hepatitis B , Hepatitis C , HIV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Telminouveau</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>